Name | carbadox |
Synonyms | carbadox CARBADOX LABOTEST-BB LT00771878 2-formylquinoxaline1,4-dioxidecarbomethoxyhydrazone 3-(2-chinoxalinylmethylen-1,4-dioxid)methylkarbazat methyl3-(2-quinoxalinylmethylene)carbazate-n1,n4-dioxide methyl 3-(quinoxalin-2-ylmethylene)carbazate 1,4-dioxide 2-(methoxycarbonylhydrazonomethyl)quinoxaline 1,4-dioxide 3-[2-QUINOXALINYLMETHYLENE]CARBAZIC ACID METHYL ESTER N,N'-DIOXIDE carbazicacid,3-(2-quinoxalinylmethylene)-,methylester,n(sup1),n(sup4)-di methyl (2E)-2-[(1,4-dioxidoquinoxalin-2-yl)methylidene]hydrazinecarboxylate 2-(2-quinoxalinylmethylene)hydrazine-carboxylic acid methyl ester n,n'-dioxide methyl (E)-[(Z)-(1-hydroxy-4-oxidoquinoxalin-2(1H)-ylidene)methyl]diazenecarboxylate |
CAS | 6804-07-5 |
EINECS | 229-879-0 |
InChI | InChI=1/C11H10N4O4/c1-19-11(16)13-12-6-8-7-14(17)9-4-2-3-5-10(9)15(8)18/h2-7H,1H3,(H,13,16)/b12-6+ |
Molecular Formula | C11H10N4O4 |
Molar Mass | 262.22 |
Density | 1.3602 (rough estimate) |
Melting Point | 239-240°C |
Boling Point | 405.47°C (rough estimate) |
Flash Point | 18°(64°F) |
Water Solubility | Soluble in 1N NaOH (50 mg/ml), and water (partly). |
Solubility | DMSO (Slightly, Sonicated) |
Appearance | powder |
Color | Yellow to Dark Yellow |
pKa | 10.51±0.46(Predicted) |
Storage Condition | 2-8°C |
Stability | Light Sensitive |
Refractive Index | 1.6000 (estimate) |
Use | Used as pharmaceutical excipients, feed additives |
In vitro study | The results of MTT assay demonstrate a dose-dependent decrease in mitochondrial activity in Vero cells at all concentrations of Carbadox. Treatment with Carbadox at the highest concentration of 160 μg/mL results in cell viability down to only 12%. Cells following Carbadox treatment show a dose-dependent increase of the DNA migration (p<0.01). The nuclear division index (NDI) reduces markedly with the increase doses of Carbadox. |
In vivo study | Alpha diversities (Shannon diversity, Heips evenness, and inverse Simpson indices) of samples from medicated piglets compare to non-medicated piglets are significantly different at 2, 3, and 4 days after continuous Carbadox, but not different in either late Carbadox or at any time during the withdrawal period. Analysis of the community structure of bacteria in animals shows significant differences at days 3 and 4 of early Carbadox treatment ([R=0.32, p=0.015] and [R=0.54, p=0.003], respectively), but not before starting antibiotic treatment (p=0.82). No significant differences in E. coli colony forming units (CFUs) are observed during the Carbadox-treatment period of the study or late in the withdrawal period. E. coli CFUs are significantly different between the medicated and non-medicated groups on day 2 after the withdrawal of Carbadox. |
Risk Codes | R45 - May cause cancer R11 - Highly Flammable R22 - Harmful if swallowed |
Safety Description | S53 - Avoid exposure - obtain special instructions before use. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | UN 1325 4.1/PG 2 |
WGK Germany | 3 |
RTECS | FE2779000 |
HS Code | 29339900 |
Hazard Class | 4.1 |
EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
biological activity | carbodox is a quinoxaline nitrogen dioxide antibiotic compound widely used in pigs of childbearing age, in order to control intestinal diseases, improve the utilization rate of feed. |
Target | Bacterial |
purpose | used as pharmaceutical excipients, feed additives |
toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |